The historical rank and industry rank for Recursion Pharmaceuticals's PB Ratio or its related term are showing as below:
MEX:RXRX'
s PB Ratio Range Over the Past 10 Years
Min: 1.37 Med: 3.36 Max: 10.52
Current: 1.85
During the past 7 years, Recursion Pharmaceuticals's highest PB Ratio was 10.52. The lowest was 1.37. And the median was 3.36.
MEX:RXRX's PB Ratio is ranked better than 66.13% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs MEX:RXRX: 1.85
During the past 12 months, Recursion Pharmaceuticals's average Book Value Per Share Growth Rate was -16.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.60% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Recursion Pharmaceuticals was -5.60% per year. The lowest was -6.50% per year. And the median was -6.05% per year.
Back to Basics: PB Ratio
Recursion Pharmaceuticals (MEX:RXRX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Recursion Pharmaceuticals PB Ratio Related Terms
Recursion Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Recursion Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Recursion Pharmaceuticals (MEX:RXRX) has a PB Ratio of 1.79 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Recursion Pharmaceuticals and its competitors. This is 47% below median its historical median of 3.36. Over the past decade, Recursion Pharmaceuticals' PB Ratio has ranged from 1.37 to 10.52. According to the industry distribution chart, Recursion Pharmaceuticals ranks #417 out of 1231 companies in the Biotechnology industry, placing it in the top 33.9%.
Is Recursion Pharmaceuticals' PB Ratio too high?
Recursion Pharmaceuticals' current PB Ratio of 1.79 is 47% below median its 10-year median of 3.36. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 10.52. The Biotechnology industry median PB Ratio is 2.93. Recursion Pharmaceuticals' value of 1.79 is 38.9% below this industry median. Based on the distribution chart, Recursion Pharmaceuticals ranks #417 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' PB Ratio compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #417 out of 1231 companies for PB Ratio. This puts Recursion Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.93. Recursion Pharmaceuticals' value of 1.79 is 38.9% below this benchmark. Historically, Recursion Pharmaceuticals' own PB Ratio has ranged from 1.37 to 10.52 over the past decade. While the company's 10-year median is 3.36 vs. the industry median of 2.93, Recursion Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recursion Pharmaceuticals's current PB Ratio of 1.79 is 38.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Recursion Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recursion Pharmaceuticals's current PB Ratio is 1.79, which is 47% below median its own 10-year median of 3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current PB Ratio is 1.79, which is 47% below median its 10-year median of 3.36 and 38.9% below the Biotechnology industry median of 2.93. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current PB Ratio is 1.79 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:RXRX:
PB Ratio: 1.79 (47% below median its 10-year median of 3.36)
GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
Industry Position: 38.9% below the Biotechnology median (#417 of 1231)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score
Get the complete analysis for MEX:RXRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
